Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib

Hepatology Research

Volumn 46, Issue 7, 2016, Pages 650-656

  Terashima, Takeshi ^a   Yamashita, Tatsuya ^a   Takata, Noboru ^a   Nakagawa, Hidetoshi ^a   Toyama, Tadashi ^a   Arai, Kuniaki ^a   Kitamura, Kazuya ^a   Yamashita, Taro ^a   Sakai, Yoshio ^a   Mizukoshi, Eishiro ^a   Honda, Masao ^a   Kaneko, Shuichi ^a  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

hepatocellular carcinoma; post progression survival; progression free survival; sorafenib; subsequent therapy

Indexed keywords

SORAFENIB;

ARTICLE; CHILD PUGH SCORE; CORRELATION ANALYSIS; HUMAN; LINEAR REGRESSION ANALYSIS; LIVER CELL CARCINOMA; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; MONOTHERAPY; OVERALL SURVIVAL; POST PROGRESSION SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SURVIVAL; SYSTEMATIC REVIEW; TIME; TIME TO PROGRESSION; TUMOR GROWTH;

EID: 84975062654     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12601     Document Type: Article

References (33)

1. Hayashi H, Okamoto I, Morita S, Taguri M, Nakagawa K. Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer. Ann Oncol 2012; 23: 1537–41.
2. Kawakami H, Okamoto I, Hayashi H, Taguri M, Morita S, Nakagawa K. Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. Eur J Cancer 2013; 49: 3003–9.
3. Petrelli F, Barni S. Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Ann Oncol 2013; 24: 186–92.
4. Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol 2010; 28: 1958–62.
5. Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst 2009; 101: 1642–9.
6. Buyse M, Burzykowski T, Carroll K et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007; 25: 5218–24.
7. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007; 25: 4562–8.
8. Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol 2013; 14: 1972–9.
9. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–917.
10. Lee JM, Yoon JH, Kim KW. Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol 2012; 39: 399–409.
11. Song MJ, Chun HJ, Song do S et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol 2012; 57: 1244–50.
12. Takizawa D, Kakizaki S, Sohara N et al. Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci 2007; 52: 3290–5.
13. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the 12Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25–34.
14. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378–90.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020–2.
16. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908–43.
17. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011; 140: 1410–26.
18. Sargent DJ, Wieand HS, Haller DG et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005; 23: 8664–70.
19. Yamashita T, Arai K, Sunagozaka H et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011; 81: 281–90.
20. Soliman H, Ringash J, Jiang H et al. Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol 2013; 31: 3980–6.
21. Miyahara K, Nouso K, Morimoto Y et al. Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma. Hepatol Res 2014; 44: 296–301
22. Terashima T, Yamashita T, Arai K et al. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Res 2014; 44: 1179–85.
23. Shao YY, Liang PC, Wu YM et al. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy. Liver Int 2013; 33: 1413–9.
24. Pressiani T, Boni C, Rimassa L et al. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis. Ann Oncol 2013; 24: 406–11.
25. Kaseb AO, Shindoh J, Patt YZ et al. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, respectability, and survival of initially unresectable hepatocellular carcinoma. Cancer 2013; 119: 3334–42.
26. Zhu AX, Kudo M, Assenat E et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312: 57–67.
27. Reig M, Rimola J, Torres F et al. Post-progression survival of patients with advanced hepatocellular carcinoma. Rationale for second line trial design. Hepatology 2013; 58: 2023–31.
28. Iavarone M, Cabibbo G, Biolato M et al. Predictors of survival of patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology. doi: 10.1002/hep.27729.
29. Edeline J, Boucher E, Rolland Y et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118: 147–56.
30. Kawaoka T, Aikata H, Murakami E et al. Evaluation the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology 2012; 83: 192–200.
31. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44: 217–31.
32. Chen PJ, Furuse J, Han KH et al. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. Liver Int 2010; 30: 1427–38.
33. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20: 2072–9.